Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer

Lung Cancer

Volumn 44, Issue 2, 2004, Pages 143-147

  Trojan, Andreas ^a   Urosevic, Mirjana ^a   Dummer, Reinhard ^a   Giger, Robin ^a   Weder, Walter ^a   Stahel, Rolf A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

CD8+ T cell; Interferon (IFN) quantitative PCR; Non small cell lung cancer (NSCLC)

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; MESSENGER RNA;

ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE COURSE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION;

CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 1842785866     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.11.004     Document Type: Article

References (31)

1. Schumacher K., Haensch W., Roefzaad C., Schlag P.M. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 61:2001;3932-3936.
2. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M.et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:2003;203-213.
3. Eerola A.K., Soini Y., Paakko P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin. Cancer Res. 6:2000;1875-1881.
4. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J.et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:2001;1107-1111.
5. Barth R.J. Jr., Mule J.J., Spiess P.J., Rosenberg S.A. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J. Exp. Med. 173:1991;647-658.
6. Dobrzanski M.J., Reome J.B., Dutton R.W. Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin. Immunol. 98:2001;70-84.
7. Sadanaga N., Nagoshi M., Lederer J.A., Joo H.G., Eberlein T.J., Goedegebuure P.S. Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells. J. Immunother. 22:1999;315-323.
8. Kammula U.S., Lee K.H., Riker A.I., Wang E., Ohnmacht G.A., Rosenberg S.A.et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol. 163:1999;6867-6875.
9. Nielsen M.B., Monsurro V., Migueles S.A., Wang E., Perez-Diez A., Lee K.H.et al. Status of activation of circulating vaccine-elicited CD8+ T cells. J. Immunol. 165:2000;2287-2296.
10. Scheibenbogen C., Romero P., Rivoltini L., Herr W., Schmittel A., Cerottini J.C.et al. Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J. Immunol. Methods. 244:2000;81-89.
11. Ortegel J.W., Staren E.D., Faber L.P., Warren W.H., Braun D.P. Modulation of tumor-infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer. Lung Cancer. 36:2002;17-25.
12. Yoshino I., Takenoyama M., Fujie H., Hanagiri T., Yoshimatsu T., Imabayashi S.et al. The induction of cytotoxic T lymphocytes against HLA-A locus-matched lung adenocarcinoma in patients with non-small cell lung cancer. Jpn. J. Cancer Res. 88:1997;743-749.
13. Johnson S.K., Kerr K.M., Chapman A.D., Kennedy M.M., King G., Cockburn J.S.et al. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer. 27:2000;27-35.
14. Tormanen-Napankangas U., Soini Y., Paakko P. High number of tumour-infiltrating lymphocytes is associated with apoptosis in non-small cell lung carcinoma. APMIS. 109:2001;525-532.
15. Yasumoto K., Takeo S., Yano T., Nakahashi H. Role of tumor-infiltrating lymphocytes in the host defense mechanism against lung cancer. J. Surg. Oncol. 38:1988;221-226.
16. Kammula U.S., Marincola F.M., Rosenberg S.A. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J. Natl. Cancer Inst. 92:2000;1336-1344.
17. Trojan A., Urosevic M., Dummer R., Nestle F.O., Stahel R.A. Real-time polymerase chain reaction monitoring of epithelial cell adhesion molecule-induced T-cell stimulation in patients with lung cancer and healthy individuals using LightCycler technology. J. Immunother. 25:2002;264-268.
18. Urosevic M., Willers J., Mueller B., Kempf W., Burg G., Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood. 99:2002;609-617.
19. Urosevic M., Kurrer M.O., Kamarashev J., Mueller B., Weder W., Burg G.et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am. J. Pathol. 159:2001;817-824.
20. Trojan A., Urosevic M., Hummerjohann J., Giger R., Schanz U., Stahel R.A. Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCR. J. Immunother. 26:2003;41-46.
21. Kerr K.M., Johnson S.K., King G., Kennedy M.M., Weir J., Jeffrey R. Partial regression in primary carcinoma of the lung: does it occur? Histopathology. 33:1998;55-63.
22. Cardi G., Mastrangelo M.J., Berd D. Depletion of T-cells with the CD4+CD45R+ phenotype in lymphocytes that infiltrate subcutaneous metastases of human melanoma. Cancer Res. 49:1989;6562-6565.
23. Rabinowich H., Cohen R., Bruderman I., Steiner Z., Klajman A. Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res. 47:1987;173-177.
24. Whiteside T.L., Miescher S., Hurlimann J., Moretta L., von Fliedner V. Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int. J. Cancer. 37:1986;803-811.
25. Asselin Paturel C., Echchakir H., Carayol G., Gay F., Opolon P., Grunenwald D.et al. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int. J. Cancer. 77:1998;7-12.
26. Huang M., Wang J., Lee P., Sharma S., Mao J.T., Meissner H.et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res. 55:1995;3847-3853.
27. Mocellin S., Wang E., Marincola F.M. Cytokines and immune response in the tumor microenvironment. J. Immunother. 24:2001;392-407.
28. Mocellin S., Panelli M.C., Wang E., Nagorsen D., Marincola F.M. The dual role of IL-10. Trends Immunol. 24:2003;36-43.
29. Koomagi R., Volm M. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int. J. Cancer. 84:1999;239-243.
30. Zaks T.Z., Chappell D.B., Rosenberg S.A., Restifo N.P. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J. Immunol. 162:1999;3273-3279.
31. Toomey D., Smyth G., Condron C., Kelly J., Byrne A.M., Kay E.et al. Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: no association with prognosis identified in 3-year follow-up. Int. J. Cancer. 103:2003;408-412.